OVERVIEW

A 3D Tour of Immuno-Oncology: Bladder Cancer is organized by Med Learning Group.

Dates:
Release Date: Aug 28, 2019
Expiration Date: Aug 28, 2020

Accreditation:
Credit Designation Statement:
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

Nursing Credit Information:
Purpose: This program would be beneficial for nurses involved in the care of patients with cancer who are treated or eligible for treatment with immunotherapy.
Credits: 1.0 ANCC Contact Hour(s)

Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

Description:
This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

Objectives:
Upon completion of the program, attendees should be able to:
• Assess the process by which tumor cells evade immune system detection and the mechanism of action of CTLA-4 and PD-1/PD-L1 inhibitors
• Analyze clinical data to identify candidates for immunotherapy based on tumor biomarkers and patient characteristics and develop/implement treatment plans that appropriately sequence and combine immunotherapies
• Examine clinical evidence supporting the use of CTLA-4 and PD-1/PD-L1 inhibitors in those three histologies and compare the efficacy of monotherapy versus combination therapy with checkpoint blockade and/or chemotherapy
• Identify immune-related adverse events (irAEs) associated with checkpoint inhibitors and discuss how to optimally manage them